Strategic Partnership in Oncology: Shilpa Biocare & Gate2Brain

Shilpa Biocare Pvt Ltd, a subsidiary of Shilpa Medicare Limited, has forged a strategic equity partnership with Gate2Brain, S.L., a biotech firm dedicated to central nervous system disease therapies. Through this agreement, Shilpa steps in as a major shareholder, supporting the CMC, manufacturing, and regulatory compliance of Gate2Brain's leading project, G2B-002. This initiative targets pediatric brain cancers, DIPG and pGBM, and has earned Orphan Drug Designation from both the US FDA and EMA. Utilizing Gate2Brain’s proprietary MiniAp4 peptide shuttle, the program significantly enhances drug delivery across the blood-brain barrier, with promising preclinical results. Human trials are eyed for fiscal year 2028.

The G2B-002 program taps into expanding oncology markets, where the glioblastoma segment is projected to hit $6.48 billion by 2035, and pediatric brain tumors are expected to reach $2.47 billion by 2031. Additionally, the DIPG segment is forecast to climb to $1.2 billion by 2035. Gate2Brain's innovative platform holds potential for other rare pediatric cancers and broader central nervous system conditions. This strategic partnership marks Shilpa's fourth equity collaboration, underscoring its commitment to driving innovation and enhancing shareholder value.

Vishnukant Bhutada, Managing Director of Shilpa Medicare Ltd, highlighted the uniqueness of Gate2Brain's CNS drug delivery technology, aligning with Shilpa’s long-term value creation mission. Meanwhile, Meritxell Teixidó Turà, CEO of Gate2Brain, emphasized the partnership's importance in advancing G2B-002's clinical journey and stressed the synergy between Gate2Brain’s scientific breakthroughs and Shilpa’s capabilities. Shilpa Medicare Limited is renowned for developing, manufacturing, and marketing pharmaceuticals across diverse therapeutic areas globally. Concurrently, Gate2Brain remains focused on peptide-based systems to improve treatment delivery for central nervous system diseases, with G2B-002 emerging as a viable brain tumor therapy candidate.